Terns Pharmaceuticals, Inc. Stock Price, News & Analysis

Terns Pharmaceuticals (NASDAQ: TERN) reported third-quarter 2025 results and corporate updates on Nov 10, 2025. Key clinical news: an ASH 2025 abstract and an oral presentation on Dec 8, 2025 will present expanded Phase 1 CARDINAL data for TERN-701, showing a 75% cumulative MMR rate by 24 weeks and 100% MMR durability at cutoff, with encouraging safety across doses. Financial highlights: $295.6M in cash, cash equivalents and marketable securities (Sept 30, 2025), expected runway into 2028. Q3 operating items: R&D $19.9M, G&A $7.8M, net loss $24.6M.

Terns Pharmaceuticals (Nasdaq: TERN) announced equity inducement awards granted to two new employees effective November 1, 2025 under the 2022 Employment Inducement Award Plan.

The company granted options to purchase a total of 252,500 shares of common stock with a 10-year term and an exercise price of $8.26 per share (closing price on October 31, 2025). The options vest over four years, subject to continued service, and were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

Terns (NASDAQ: TERN) announced that Phase 1 CARDINAL data for TERN-701, an allosteric BCR::ABL1 inhibitor for previously treated CML, was selected for oral presentation at the 67th ASH Annual Meeting on December 8, 2025.

As of the June 30, 2025 cutoff (55 enrolled; 32 efficacy-evaluable), cumulative MMR was 75% (24/32) by 24 weeks, with 64% (14/22) achieving MMR and 100% (10/10) maintaining MMR. Safety was encouraging: no DLTs, MTD not reached, 87% remained on treatment, mostly low-grade TEAEs. Company will host an investor webcast on December 8, 2025 at 4:30pm ET.

Terns (NASDAQ: TERN) announced topline 12-week Phase 2 results for oral GLP-1RA TERN-601 on October 21, 2025. The trial showed up to 4.6% placebo-adjusted weight loss at doses >500 mg but did not meet the company’s threshold for a differentiated oral GLP-1RA and likely precludes further development. Safety findings included mainly mild-to-moderate GI adverse events (nausea 56%, vomiting 26.9%) and three post-treatment grade 3 liver enzyme elevations, two adjudicated as drug related. Terns will not advance TERN-601 or invest further in metabolic assets and will focus on TERN-701 for CML, with clinical data expected this quarter.

Terns Pharmaceuticals (Nasdaq: TERN) announced on Oct 2, 2025 that it granted equity inducement awards to four new employees under its 2022 Employment Inducement Award Plan, approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4).

The Company granted options to purchase a total of 118,000 shares of common stock, with a 10-year term and an exercise price of $7.81 per share (closing price on Oct 1, 2025). The options vest over four years, subject to continued service.

Terns Pharmaceuticals (Nasdaq: TERN) announced an upcoming investor educational webinar focused on TERN-701, their investigational next-generation oral BCR-ABL inhibitor for chronic myeloid leukemia (CML). The webinar, scheduled for September 3, 2025 at 4:30 p.m. ET, will precede the anticipated Phase 1 data release in Q4 2025.

The presentation will feature key executives including CEO Amy Burroughs, CMO Emil Kuriakose, and CDO Scott Harris. They will discuss TERN-701's potential best-in-class profile, Phase 1 data benchmarks, and its positioning in the CML treatment landscape. The drug specifically targets the ABL myristoyl pocket and is being developed as an allosteric inhibitor.

Terns Pharmaceuticals (NASDAQ:TERN) reported Q2 2025 financial results and provided updates on its clinical programs. The company highlighted progress in two key areas: TERN-701 for chronic myeloid leukemia (CML) and TERN-601 for obesity.

Key financial metrics include $315.4 million in cash and equivalents, providing runway into 2028, and a net loss of $24.1 million for Q2 2025. The company plans to focus on oncology, particularly advancing TERN-701, while seeking partners for its metabolic assets.

Two major clinical readouts are expected in Q4 2025: efficacy and safety data from the Phase 1 CARDINAL trial of TERN-701, including 6-month major molecular response rates, and 12-week data from the completed Phase 2 FALCON trial of TERN-601 for obesity.

Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage biopharmaceutical company focused on developing small-molecule treatments for oncology and obesity, has granted equity inducement awards to two new employees. The company's new Chief People Officer Robin Andrulevich received options to purchase 500,000 shares of common stock, while another non-executive employee received options for 125,000 shares.

The options were granted under the 2022 Employment Inducement Award Plan with an exercise price of $5.47 per share, the closing price on August 1, 2025. These 10-year term options vest over four years, contingent on continued employment.

Terns Pharmaceuticals (NASDAQ:TERN) presented positive Phase 1 data for TERN-601, their novel once-daily oral GLP-1R agonist for obesity treatment, at the 85th ADA Scientific Sessions. The 28-day study demonstrated significant dose-dependent weight loss up to 5.5%, with 67% of patients losing 5% or more body weight at the top dose.

The drug showed a differentiated safety profile with no treatment-related interruptions and over 95% of GI adverse events being mild, despite rapid dose titration. TERN-601 features unique pharmaceutical properties allowing 24-hour target coverage and can be administered with or without food and various acid-reducing medications.

The company also announced completion of enrollment for their Phase 2 FALCON trial, with 12-week topline data expected in Q4 2025.